Leo Pharma pays up to $435M for rights to Tanabe's oral therapy for sun-triggered skin conditions
Leo Pharma has agreed to pay Japan's Tanabe Pharma as much as $435 million in upfront and near-term fees to license an oral medication targeting two inherited skin disorders that cause pain upon sun exposure. The Danish company will take over development and commercialization of the drug, which addresses a rare patient population with significant unmet need. Financial terms include milestone-based payments beyond the initial sum, though specific amounts were not disclosed.
Related stories
BioMarin acquires early-stage bone disease candidate in modest deal · Drug development
Regeneron secures approval for ultra-rare bone disorder drug · Drug development
Roche pays $190M upfront for Hanmi's muscle-sparing obesity drug · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure.” Browse more stories.